Studies at home and abroad have proved that strengthening immunization with COVID-19 vaccine can enhance the protection effectiveness and prolong the protection period. Up to now, more than 23 million citizens in this city have completed the whole vaccination of COVID-19 vaccine, of which120,000 citizens have completed the intensive immunization. Citizens who have not been vaccinated need to complete the vaccination as soon as possible. According to the deployment of joint prevention and control mechanism in the State Council, the city began to use recombinant COVID-19 inhalation vaccine to strengthen immunization on October 26th, 2022.
For people aged 18 years and above who have been vaccinated with inactivated vaccine produced by China Biotechnology Co., Ltd., Wuhan Institute of Biological Products Co., Ltd. and Beijing Kexing Zhongwei Biotechnology Co., Ltd. and intramuscular recombinant COVID-19 vaccine produced by Kangxinuo Biotechnology Co., Ltd. for six months, they can choose to use recombinant COVID-19 vaccine inhalers for 1 dose booster immunization. This intensive immunization is free of charge.
According to the relevant national requirements, citizens only need to be vaccinated with 1 dose of low homologous booster immunization or sequential booster immunization.
From June 25, 2022, 10, eligible citizens can make an online appointment for supplementary immunization through the "Healthy Cloud" app. At the appointed time, I will bring my valid ID card to the appointed vaccination clinic for intensive immunization. When the elderly aged 70 and over are vaccinated, they should be accompanied by family members or volunteers.
Foreigners in Shanghai, compatriots from Hong Kong, Macao and Taiwan should be immunized by inhaling recombinant COVID-19 vaccine, which is still implemented in accordance with the relevant policies and requirements of previous immunization.
1. What is recombinant COVID-19 inhalation vaccine?
Answer: The recombinant COVID-19 vaccine for inhalation is to transport the genetic material expressing S protein into human body by adenovirus vector which is harmless to human body. The vaccine is atomized into tiny particles by atomizer, and then reaches the lung tissue through inhalation and oral respiration, thus stimulating the triple immunity of mucosa, body fluid and cells.
2. What are the conditions for inoculation of recombinant COVID-19 inhalation vaccine?
A: At this stage, people aged 65,438+08 and above who have been vaccinated with inactivated vaccine produced by Sinopharm China Biotechnology Co., Ltd., Wuhan Institute of Biological Products, Beijing Kexing Zhongwei Biotechnology Co., Ltd. and recombinant COVID-19 vaccine produced by Kangxinuo Biotechnology Co., Ltd. for six months can use 65,438+0 doses of recombinant COVID-19 inhalation vaccine for booster immunization. Recombinant COVID-19 vaccine for inhalation will not be used for basic immunization for the time being.
All kinds of people only need to be vaccinated with 1 dose of low homologous booster immunization or sequential booster immunization.
Q3。 What is the inhalation dose of recombinant COVID-19 vaccine? A
Each dose was 0. 1 ml.
Can people above Q4.60 be vaccinated? Can people below 18 be vaccinated with recombinant COVID-19 vaccine inhalers? A
At present, the recommended vaccination population for inhalation dosage forms is 18 years old and above.
Q5。 What is the effect of enhancing immunization with recombinant COVID-19 vaccine for inhalation? A
At present, the clinical study of sequential booster immunization with recombinant COVID-19 vaccine and inactivated novel coronavirus vaccine for inhalation in healthy adults aged 65,438+08 and above in China shows that sequential booster immunization with recombinant COVID-19 vaccine and inactivated vaccine for inhalation can significantly enhance the immune response.
Q6。 What is the immune persistence of recombinant COVID-19 vaccine for inhalation?
A. The study of immune persistence showed that after 6 months of heterogeneous inoculation with recombinant COVID-19 vaccine for inhalation, the neutralizing antibody remained at a high level.
Q7。 What is the safety of recombinant COVID-19 vaccine for inhalation?
A The safety study of tens of thousands of people showed that the recombinant COVID-19 inhalation vaccine was safe for people over 18 years old, and no serious adverse reactions were found.
Q8。 What are the contraindications for inhalation of recombinant COVID-19 vaccine?
Allergic to the active ingredients in this product, any inactive ingredients, substances used in the production process, or allergic to similar vaccines.
People who have had severe allergic reactions to vaccines in the past.
People with uncontrolled epilepsy and other progressive neurological diseases have a history of Guillain-Barre syndrome.
Patients with fever, acute disease, acute attack of chronic disease or uncontrolled serious chronic disease;
Pregnant women.
Q9。 Can patients with chronic diseases be vaccinated with recombinant COVID-19 vaccine for inhalation?
A: According to the technical guidelines for vaccination in COVID-19, patients with chronic diseases are at high risk of serious illness and death after being infected with COVID-19 virus. Patients with chronic diseases with stable health and good drug control are recommended to be vaccinated. Vaccination should be suspended during acute attack of chronic diseases. Have a history or family history of convulsion, epilepsy, encephalopathy or mental illness; Have a history of asthma, chronic obstructive pulmonary disease, pulmonary fibrosis and other basic diseases or abnormal lung function; Use with caution in patients with impaired immune function.
Q 10。 Does the cured population in COVID-19 need to be vaccinated with recombinant COVID-19 inhalation vaccine? A
According to "Technical Guidelines for Vaccination in COVID-19", it is very rare for COVID-19 to be reinfected within 6 months after infection. In the past, people infected with COVID-19 virus could be vaccinated with 1 dose after 6 months on the basis of full notification.
Q 1 1。 Can people with allergies be vaccinated with recombinant COVID-19 vaccine for inhalation?
A "Technical Guide to Vaccination in COVID-19" clarifies that people who have had severe allergic reactions to vaccines in the past are contraindications for vaccination in COVID-19; In addition, we should also consider the severity of allergies and allergens and follow the doctor's advice.
12. How to inoculate recombinant COVID-19 inhalation vaccine?
A Please practice several times before inhaling, and then start the formal vaccination.
Step 1: Take a deep breath first;
Step 2: put the nozzle of the atomizing cup in your mouth and inhale deeply until there is no fog in the cup;
Step 3: Hold your breath for more than 5 seconds, then breathe normally, and the inoculation is over.
13. under what circumstances do you need to inhale recombinant COVID-19 vaccine for inhalation again on the spot?
A. There is obvious misty gas in the atomizing cup after inhalation;
Cough and early expiration occur when inhaling.
Suction failure requires another dose of vaccine, and repeated inhalation is only allowed once.
Q 14。 What should I pay attention to after inoculating recombinant COVID-19 inhalation vaccine?
A should be observed at the scene for at least 30 minutes after inoculation; Avoid contact with previously known allergens and common allergens within one week after inoculation, and try not to drink alcohol or eat spicy food or seafood. It is recommended to eat lightly and drink plenty of water.
Q 15。 What are the possible adverse reactions after vaccination with recombinant COVID-19 vaccine for inhalation?
A Common systemic adverse reactions include fatigue, headache, fever, dry mouth, sore throat and other symptoms, which can be recovered without special treatment.
Q 16。 Will inoculation of recombinant COVID-19 vaccine for inhalation affect the results of nucleic acid detection and antigen detection?
An adenovirus vector COVID-19 vaccine is characterized by containing only the gene sequence of S protein, expressing antigen in human cells, and not containing nucleic acid detection site open reading frame 1ab and nucleocapsid protein. Therefore, vaccination with this vaccine will not lead to COVID-19's positive nucleic acid test.